The official blog of the Lung Institute.

Challenging the Status Quo with Cells

22 Mar 2015
| Under Lung Disease, Treatments | Posted by
Stem Cells Lung Institute

Looking back on history, we remember a time when women didn’t have the rights that they do now. Prior to 1919, women didn’t have any way to express their thoughts and desires through public policy. As a result of first-wave feminists such as Elizabeth Cady Stanton and Susan B. Anthony questioning the status quo, 1920 marked the first year that women could vote. This major social change noted a moment in history when women finally had the right to take control of their own life. Since then, women have been continuously working for gender equality and new ways to express their freedom.

Consider the years that women were trapped; they remained silent while searching for a way they could affect society and be heard. The right to vote made it possible for women to be involved in their own everyday life. Since we live in a democracy, public policy is decided through voting, but without the ability to partake in the national conversation, the lives of women were being decided by others. In many ways, the history of women’s suffrage is similar to the road to regenerative medicine advancements.

Much like women fighting for equality, patients have been fighting for a new way to treat their chronic lung disease. Now, with the advancement of cellular therapy, sufferers of chronic lung disease are no longer limited to the confines of traditional medicine—which simply involves managing symptoms rather than their disease. Cellular therapy, much like women’s voting rights, opens the door to people taking control of their life by giving people a voice.

For years, people accepted the status quo, and for people suffering from a chronic lung disease such as COPD or interstitial lung disease, the status quo meant a constant struggle for oxygen, endless shortness of breath and a life with no hope. As an incurable disease, most sufferers felt that they didn’t have any options. But today, lung disease sufferers are no longer stuck living in the status quo.

Cellular therapy provides another option for sufferers to breathe easier. The Lung Institute team is composed of driven individuals who are dedicated to challenging the incurable with regenerative medicine. People are no longer forced to accept the fate of continual disease progression and an eventual lung transplant or invasive lung reduction. Cellular therapy harnesses the innate healing power of a patient’s own cells in order to help promote healing to damaged lung tissue.

Today, lung disease can be treated with adult cells harvested from the patient’s own blood or bone marrow to replace damaged lung cells with healthy ones. According to the Lung Institute’s website, lunginstitute.com, this innovative procedure may slow the progression of the disease, but it may improve lung function and reduce inflammation.

Much like the fight for women’s voting rights, doctors and patients have been diligently looking for a new way to treat lung disease. Now, with the advancement of cellular therapy, patients finally have a way to combat disease progression and live better. As with any change, some physicians and patients may be slower to adopt new ideas while clinging to traditional approaches; however, just as social change made it possible for women to have a voice in the government, clinical advancements like cellular therapy are making it possible for patients to have a voice in their healthcare. If the fight for equality is any sign of the future of cellular therapy, there is no doubt that cells will become the status quo for treating lung disease.

For more information about cellular therapy, contact the Lung Institute at (800) 729-3065.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.